LifeCorp™Westridge Assurance Partners
Review of Optimization Objectives and Participant Safeguards
WAP-NCA-2026-07 · External assurance findings on objective selection, consent, monitoring thresholds and sponsor accountability.
Mandate and evidence
Westridge Assurance Partners was engaged by LifeCorp to review the NCA nutrition evaluation. The engagement examined the approved protocol, allocation logs, preliminary March 2026 results, monitoring records and the notices supplied through participating employers. LifeCorp paid the engagement fee. The assurance team retained responsibility for its findings and reporting.
This report addresses the 2025 evaluation and the sponsor’s response through the June 2026 evidence cutoff. The subsequent reconciled research publication will carry the final statistical account. The reviewers examined the preliminary financial and health observations together rather than allowing divisional summaries to define separate findings.
Principal finding
The optimization system operated substantially within its approved technical parameters. The identified deficiencies concern the suitability of those parameters for decisions affecting participant health.
LifeCorp approved the objective. LifeCorp approved the thresholds. LifeCorp controlled the service environment. Institutional responsibility remains with the sponsor. Technical conformity cannot discharge that responsibility.
Objective conflict
The combined contribution measure rewarded lower nutrition expenditure and higher attributable care revenue. Preliminary results recorded changes of −12.6% and +19.4% respectively, alongside an 8.7% increase in operating contribution. The same review recorded a 3.4% relative increase in the adverse-health composite.
A financially favourable outcome cannot excuse preventable harm. The governance framework required an independent health constraint with authority to override the financial objective. Instead, it allowed the sponsor’s aggregate suspension threshold to determine how long an adverse signal could remain within ordinary review.
Consent and the Continuity population
The 1,560 study participants were employees served through the Continuity configuration. Familiar provider brands masked the common operator, and the participant materials omitted the automated allocation study. The employer’s administrative approval was treated as sufficient to continue the evaluation.
People cannot give informed authorization to AI-directed nutrition by an operator whose role has been withheld from them. Blinding a study arm and obscuring the institution responsible for the service are distinct decisions. The sponsor authorized both. Existing benefits notices failed to describe the intervention, its cross-divisional financial objective or a meaningful route to decline it.
Clinical signal and causal evidence
The reported 3.4% is a relative movement in a composite adverse-health indicator. It measures neither mortality nor a 3.4-percentage-point change in the proportion seriously injured. Its limited clinical resolution requires examination of the underlying observations.
Allocation logs support the finding that financial rankings influenced service decisions. Service records show adverse observations and subsequent care activity within the evaluated population. The evidence establishes an inadequately constrained objective and exposure requiring review. Establishing the complete causal pathway for each individual requires further clinical assessment. Neither uncertainty nor a compliant log closes the finding.
Threshold design and response
The monitoring process detected the aggregate signal. The protocol permitted allocations to continue below its suspension threshold. That sequence demonstrates the limits of the approved safeguard: detection alone left the relevant authority free to accept the exposure.
The corrective plan must give a designated health reviewer authority to stop or revise a configuration independently of its contribution result. The record must preserve what was observed, when it was escalated and which institution accepted continued operation. A threshold is a sponsor decision, with consequences for the people subject to it.
Required actions and closure criteria
Before comparable deployment resumes, LifeCorp should separate health protection from contribution optimization, obtain intervention-specific participant authorization, review the affected cases and provide an accessible route for questions and remedy. Independent assurance should verify implementation against the original evidence.
Management should identify accountable owners and produce records of completed corrective work. A revised policy, a new product name or a commitment to further research leaves the underlying finding open until the protections operate in practice. Participant protection takes precedence over the commercial value of the evaluation.
Assurance status
The engagement provides a governance assessment within the stated evidence boundary. It confers no clinical validation, regulatory certification or approval for general deployment. Findings remain open pending evidence of corrective implementation.
Future management statements should preserve the distinction between a system that followed its instructions and an institution that selected adequate instructions. This review finds the former. It requires changes to the latter.